Anti-CD20-Mediated B Cell Depletion Is Associated With Bone Preservation in Lymphoma Patients and Bone Mass Increase in Mice

Anti-CD20-Mediated B Cell Depletion Is Associated With Bone Preservation in Lymphoma Patients and Bone Mass Increase in Mice

Immunotherapy with anti-CD20-specific antibodies (rituximab), has become the standard of care for B cell lymphoproliferative disorders and many autoimmune diseases. In rheumatological patients the effect of rituximab on bone mass yielded conflicting results, while in lymphoma patients it has not yet...

Full description

Bibliographic Details
Main Authors: Albert Kolomansky, Irit Kaye, Nathalie Ben-Califa, Anton Gorodov, Zamzam Awida, Ofer Sadovnic, Maria Ibrahim, Tamar Liron, Sahar Hiram-Bab, Howard S. Oster, Nadav Sarid, Chava Perry, Yankel Gabet, Moshe Mittelman, Drorit Neumann
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Immunology
Subjects:
rituximab
follicular lymphoma
anti-CD20 antibodies
RANKL (receptor activator for nuclear factor k B ligand)
B cell depletion
bone density
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.561294/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.561294/full

Similar Items